Article Image

The Dangers of Compounded Obesity Medications

Op-Med is a collection of original articles contributed by Doximity members.

As a society, we stand on the brink of a revolution in treating obesity, a condition affecting millions and a leading cause of numerous health problems worldwide. The recent surge in the popularity of GLP-1 agonists, like semaglutide (Wegovy) and tirzepatide (Zepbound), has been a beacon of hope, showcasing significant weight loss and health improvements. However, as we navigate this promising landscape, an alarming trend jeopardizes patient safety: the proliferation of compounded medications and the lack of a comprehensive treatment approach.

Obesity is a complex, multifactorial disease that extends beyond just the simplistic treatment plan of "eat less and move more." It encompasses genetic, physiological, environmental, and psychological factors. Losing weight can trigger a compensatory response that escalates hunger, making the journey toward a healthier self a battle against one's own physiology. The recent advancements in GLP-1 medications are indeed groundbreaking, counteracting hunger, cravings, and the incessant food "noise" which plagues those striving for weight loss. Yet, these medications are not a panacea. They are most effective and safest when used as part of a broader multidisciplinary approach that includes dietary changes, physical activity, psychological support, and regular medical monitoring.

The rise of online telemedicine clinics and medispas offering quick access to compounded versions of these drugs without proper medical oversight is deeply concerning. The FDA has issued warnings about the potential dangers of these compounded drugs, which often lack the rigorous testing and quality assurance of their FDA-approved counterparts. There are no generic forms of these medications, though compounded drugs are often marketed as such. These unauthorized versions may lead to severe side effects, diminished efficacy, or other unexpected health issues. Also, unlike the FDA approved anti-obesity medications that come in single-dose pens, these compounded versions often come in vials that patients must dispense themselves, possibly leading to incorrect dosages. It's not just a matter of legality; it's a matter of patient safety and ethics.

Recently, a landmark collaboration among three leading obesity expert organizations (Obesity Medicine Association, The Obesity Society, and Obesity Action Coalition) culminated in a critical statement addressing the use of GLP-1 therapies for weight loss. These organizations, united in their expertise and concern, have raised a red flag about the risks associated with compounded alternatives to FDA-approved treatments like Wegovy and Zepbound. These compounded versions could contain impurities or other non-pharmaceutical additives, posing serious health risks. Given these concerns, the organizations strongly advise against the use of such alternatives, urging patients to approach obesity treatment with the same caution and diligence as any other serious medical condition, relying only on proven, FDA-approved therapies.

Patients desperate for weight loss solutions may turn to these options. However, this shortcut can have dire consequences. Some online clinics and medispas provide these drugs haphazardly without thoroughly assessing a patient's health history and other medications. These medications require close oversight because dosages often need to be adjusted over time to ensure efficacy and minimize side effects. This level of personalized care is often absent in these unregulated settings. Additionally, weight loss medication can lead to muscle loss, gastrointestinal issues, and other side effects if not properly monitored, especially when not coupled with lifestyle and dietary changes. Obesity is a chronic condition and will likely require persistent treatment, so patients assuming they can take these medications for a few months and then discontinue will unfortunately have a high risk of weight regain, especially if sustainable lifestyle modifications are not implemented.

We must understand that obesity treatment is not a one-size-fits-all solution. It should emphasize a comprehensive approach, including nutrition, exercise, behavioral counseling, and medical support. We should recognize medications as a potential option for some, but also prioritize the safety and long-term well-being of patients by integrating these tools into a broader customized treatment plan. The goal is not just weight loss but the enhancement of overall health and well-being.

There is a pressing need for vigilance against the unauthorized and unsafe distribution of these powerful drugs. Counterfeit and compounded medications not only undermine the efforts of health care practitioners but also endanger patients. It's a call to action for stricter regulations, better patient education, and a more informed public discourse. And the journey is far from over. Our food environment is not just a minefield of unhealthy temptations, but also a marketplace dominated by oversized portions and ultra-processed foods. Beyond dietary hurdles, psychosocial factors, such as stress, depression, and lack of sleep, compound the problem. Socioeconomic constraints further complicate matters, restricting access to nutritious foods and perpetuating an ever more sedentary lifestyle that many of us find ourselves ensnared in. The rate of obesity in our nation persistently rises each year. While medications provide a potential tool for some, their high cost combined with inadequate insurance coverage remains a significant barrier for many. A multifaceted approach is imperative to truly address this epidemic.

Obesity is a chronic disease, much like hypertension or diabetes, and requires long-term management. It's time we shift the narrative from quick fixes to sustainable health. By embracing a multidisciplinary approach, we can provide patients with the tools, support, and medical care they need to achieve and maintain a healthy weight, improve their quality of life, and reduce the risk of associated health conditions. Let's move beyond the criticisms and misunderstandings of the past, acknowledge the complexity of obesity, and commit to comprehensive, compassionate, and proper care for those we serve.

All opinions published on Op-Med are the author’s and do not reflect the official position of Doximity or its editors. Op-Med is a safe space for free expression and diverse perspectives. For more information, or to submit your own opinion, please see our submission guidelines or email

More from Op-Med